L'OFFICIEL, Subsidiary of The Generation Essentials Group, Hosts a Groundbreaking Fashion Show at the London Stock Exchange

L'OFFICIEL, Subsidiary of The Generation Essentials Group, Hosts a Groundbreaking Fashion Show at the London Stock Exchange

PARIS and NEW YORK and LONDON, Dec. 15, 2025 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD) and The Generation Essentials Group ("TGE", NYSE & LSE: TGE), a subsidiary of AMTD...

Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group

TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant...

GIBO Announces Strategic Collaboration with E Total Technology Sdn Bhd to Accelerate Deployment of AI Compute Centers Featuring NVIDIA's Most Advanced Chips

GIBO Announces Strategic Collaboration with E Total Technology Sdn Bhd to Accelerate Deployment of AI Compute Centers Featuring NVIDIA's Most Advanced Chips

KUALA LUMPUR, Malaysia, Dec. 15, 2025 /PRNewswire/ -- GIBO Holdings Ltd. (NASDAQ: GIBO) today announced a strategic collaboration with Malaysia-based technology and infrastructure solutions provider E Total Technology Sdn Bhd, under which the...

Emeren Group Announces Completion of Merger

Emeren Group Announces Completion of Merger

NORWALK, Conn., Dec. 15, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced the completion of the merger contemplated by the...

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug...

MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine

MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine

The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that MEDEZE Group...

Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once - daily or potentially once-weekly oral dosing. - ASC50 had...

Medit Announces 2025 Year-End Promotion

Medit Announces 2025 Year-End Promotion

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Medit, a global leader in 3D dental scanning solutions, announced the launch of "Medit's 2025 End of Year Promotion," a limited-time campaign delivering significant benefits to dental professionals...

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in...

Agricultural Corporation Joeunsul Co., Ltd. Announces Entry into Vietnam Market, Accelerating Southeast Asia Expansion with "Cheonbihyang"

Agricultural Corporation Joeunsul Co., Ltd. Announces Entry into Vietnam Market, Accelerating Southeast Asia Expansion with "Cheonbihyang"

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Korean traditional liquor producer Agricultural Corporation Joeunsul Co., Ltd. has announced its plans to enter the Vietnamese market, spearheading its Southeast Asia expansion with its flagship...

  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...
  • 145
  • menu
    menu